Inhibikase Therapeutics Inc (IKT) stock news · $215.2M cap
Inhibikase Therapeutics Inc (IKT) is a biotechnology company listed on US.
This IKT news page leads with what Inhibikase Therapeutics Inc filed — not a scraped headline mill.
No cached 8-K sentence for IKT yet. We will not pad this page with generic market recap.
Latest reported IKT revenue for 2026-06-30 was $0. Net income was -$19.6M. IKT currently screens at market cap $215.2M.
EDGAR remains the official archive. Lician caches the exhibit so you can read what changed without a wire story.
Not investment advice. For the model open the IKT stock page; for the tape open the quote page.
IKT stock news FAQ
What is IKT's latest net income?
Latest cached Inhibikase Therapeutics Inc (IKT) net income was -$19.6M. Statements: https://lician.com/financials/ikt
What is IKT's market cap?
Inhibikase Therapeutics Inc (IKT) market cap is $215.2M on the latest cached fundamentals snapshot.
What kind of company is IKT?
Inhibikase Therapeutics Inc (IKT) is a biotechnology company listed on US.
Where is IKT stock news listed?
Cached stock news for Inhibikase Therapeutics Inc (IKT) is listed at https://lician.com/news/ikt. Filings: https://lician.com/sec/ikt
Not investment advice.